[Positron emission tomography using 18F-fluorodeoxyglucose in the management of nonsmall cell lung cancers in 2006].
Technological progress and numerous published studies allow to estimate the best place of the 18F-fluorodeoxyglucose positron emission tomography, a real functional metabolic imagery, in the clinical and therapeutic strategy of non small cell lung cancers.
Vaylet
F
F
Service des maladies respiratoires, hôpital d'instruction des armées Percy, 101, avenue Henri-Barbusse, 92141 Clamart, France. vaylet.fabien@gmail.com
Bonnichon
A
A
Salles
Y
Y
Gontier
E
E
Bonardel
G
G
Lefloch
H
H
Mairovitz
A
A
Mantzarides
M
M
Niang
A
A
Marotel
C
C
Foehrenbach
H
H
D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000556:secondary; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging; D010347:Patient Care Planning; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18